Press Releases

ROSEMONT, Ill., Oct. 22, 2019 /PRNewswire/ -- Halloween is upon us! Pumpkin patches, haunted houses and trick-or-treating are fun and festive ways to celebrate this holiday, but the excitement of these activities can quickly turn dangerous if you're not careful. The

NEW YORK, Oct. 22, 2019 /PRNewswire/ -- The New York Academy of Medicine honored Robert F. Smith, Chairman and CEO of Vista Equity Partners; Cynthia Germanotta, President and Co-Founder of the Born This Way Foundation; and Harlem Capital at its Access: Health Gala on October 21, 2019

DUBLIN, Oct. 22, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 third quarter financial results on Tuesday, November 5, 2019, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at

SAN DIEGO, Calif., Oct. 22, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new open-label extension data from the Phase 2 OASIS trial for its investigati

THOUSAND OAKS, Calif., Oct. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the fourth quarter of 2019. The dividend will be paid on Dec. 6, 2019, to all stockholders of record as of the close of business on

SEATTLE, Oct. 22, 2019 /PRNewswire/ -- IntuitiveX (IX), a Seattle-based life sciences consultancy and incubator, continues to demonstrate its ability to create and generate demand for new intellectual property (IP) with the recent sale of NavLab's initial IP.

PROVIDENCE, R.I., Oct. 22, 2019 /PRNewswire/ -- Announced today, Chugai Pharmaceutical Co., Ltd. ("Chugai"), a member of the Roche Group, will extend the company's licensed access to the Immunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc. ("EpiVax").

CHICAGO, Oct. 22, 2019 /PRNewswire/ -- Nearly all U.S. hospitals (96%) now recognize the importance of, and have set, cost reduction targets, yet fewer than 1 in 4 respondents have achieved "most" or "all" of their cost transformation goals, especially in non-traditional, high-opportunity cost reduction areas — such as lowering unwarranted clinical variation &

FRAMINGHAM, Mass., Oct. 22, 2019 /PRNewswire/ -- BERG, the clinical stage biopharmaceutical company that uses artificial intelligence (AI) to discover the biology of underlying disease, today announced results from a preclinical study of its investigational drug BPM 31510 (novel ubidecarenone formulation) in glioblastoma models. The study, presented as a poster at the So

HOUSTON, Oct. 22, 2019 /PRNewswire/ -- Breast cancer is the second-leading cause of cancer death among women in the U.S. which is why Gordmans, as part of the Stage community of stores, is renewing its pl